Navigation Links
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Date:9/30/2009

l. One subject did not complete the trial due to personal reasons and one other subject did not complete the trial due to a serious adverse event, cholecystitis (gall stones), which was judged not related to the study drug.

Based on these important findings, the Company now plans to adjust its future dosing. Expanded Phase 2 planning is moving forward to include Phase 2 IVUS trials, a Phase 2 dosing trial and a Phase 2 combination statin trial. The IVUS Steering Committee is chaired by Dr. Steven Nissen, Chairman of the Cleveland Clinic Department of Cardiovascular Medicine, and the principal investigator is Dr. Stephen Nicholls, Medical Director of Intravascular Ultrasound at Cleveland Clinic.

"The results we have observed in our second clinical trial illustrate an important emerging pattern of predictability. To date 162 human subjects have received RVX-208 which has consistently demonstrated itself to be a well tolerated and safe therapeutic," stated Dr. Jan Johansson Senior Vice President of Medical Affairs at Resverlogix. "It is important to note that in addition to the increases in ApoA-I and HDL, we also saw very pronounced increases in alpha-1 HDL, another important marker for CVD risk. The landmark Framingham Offspring Study clearly illustrated that among HDL and LDL, alpha-1 HDL was a more critically important marker for CVD protection," Dr. Johansson added.

Developing small molecules that increase ApoA-I would satisfy a huge unmet medical need because CVD treatment with statins, the current standard of care, only stabilizes atherosclerosis and reduces cardiovascular risk by 30%. A recent cost-benefit pharmacoeconomic analysis of ApoA-I therapy for CVD estimated that a 1% and 5% regression of atherosclerosis would save the U.S. health care system and employers between US $22.9 billion and US $76.8 billion annually over and above statin therapy. The analysis assumes ApoA-I therapy will be
'/>"/>

Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
2. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
3. Resverlogix Provides Quarterly Update
4. Resverlogix Board of Directors Update
5. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
6. Resverlogix Announces Closing of Debt Redemption
7. Resverlogix Eliminates Sixty Percent of Remaining Debt
8. Resverlogix Issues a Management Statement
9. Resverlogix Board of Directors Update
10. Resverlogix Notice of Conference Call & Webcast
11. Jan Gray Joins Resverlogix Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015 As part of its ... (BDWMC), Sun Health Foundation funded a $3.25 million project ... pharmacy with the most up-to-date features and technology. , ... The pharmacy's 45 staff members will begin moving from ... in the coming days. , The current pharmacy ...
(Date:5/20/2015)... SAN FRANCISCO, Calif. , May 20, 2015 ... VCYT ) today presented preliminary data demonstrating the ... distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial ... The findings suggest the classifier,s potential to help ... surgery to resolve ambiguity in IPF diagnosis – ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 The global ... of 22.3% during the forecast period of 2015 to ... increasingly being used in drug discovery and development process ... market growth. In addition to this,heavy investments by key ... applications are also propelling market growth. Browse 113 market ...
(Date:5/20/2015)... 20, 2015  Cypher Genomics, Inc., a leading ... Celgene Corporation to apply Cypher,s Coral TM ... with patient response to innovative medicines. The information ... accelerate patient access to the right medicine at ... and development and potentially inform new companion diagnostics.  ...
Breaking Biology Technology:Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2
... Bottle , ... Concord, NH (PRWEB) July 25, 2008 -- These days, ... sipping water from a SIGG bottle. "Carrying a SIGG bottle has become ... green," said Debby de Moulpied, founder and owner of Real Green Goods, ...
... Product Sales Driven by Robust MRSA Growth, SUNNYVALE, ... for the second quarter of 2008 of $42.1,million, an ... 2007. Net,loss was $7.5 million, or $(0.13) per share, ... loss of $5.2 million, or $(0.10) per share, in ...
... ROCM ) will announce quarterly results after,financial markets ... then,hold a quarterly conference call to discuss its earnings ... time (5:00 p.m. eastern time)., This call is ... Medical,s website at http://www.rocm.com . To listen live ...
Cached Biology Technology:SIGG Water Bottles: Hip But Not Necessarily Green; Were Madonna and Cindy Crawford Hoodwinked? 2Cepheid Reports Second Quarter Revenue of $42.1 Million 2Cepheid Reports Second Quarter Revenue of $42.1 Million 3Cepheid Reports Second Quarter Revenue of $42.1 Million 4Cepheid Reports Second Quarter Revenue of $42.1 Million 5Cepheid Reports Second Quarter Revenue of $42.1 Million 6Cepheid Reports Second Quarter Revenue of $42.1 Million 7Cepheid Reports Second Quarter Revenue of $42.1 Million 8Cepheid Reports Second Quarter Revenue of $42.1 Million 9Cepheid Reports Second Quarter Revenue of $42.1 Million 10Cepheid Reports Second Quarter Revenue of $42.1 Million 11Cepheid Reports Second Quarter Revenue of $42.1 Million 12Cepheid Reports Second Quarter Revenue of $42.1 Million 13Rochester Medical Announces Third Quarter 2008 Earnings Conference Call July 31, 2008 2
(Date:5/21/2015)... BOSTON , May 21, 2015 ... scientific potential of music for health, today announced a ... (BerkleeICE) . The partnership will center on collaboration on ...  As a first step in the collaboration, The Sync ... course on "Music as Medicine" in the 2015-2016 academic ...
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS ... had a strong showing at AUVSI,s Unmanned 2015 ... representatives of Ohio,s UAS industry met ... abroad from all points along the UAS ecosystem. ... Coalition,s (DDC) Vice President for Aerospace Rich Knoll . ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... your skin crawla bug that crawls onto your lips while ... skin, bites, then gorges on your blood. And if that,s ... on a potentially deadly disease. Now Jean-Paul Paluzzi, ... Mississauga, believes that manipulating physiology to prevent the insects from ...
... April 29 A small piece of RNA appears to ... fibrosis (IPF), according to lung disease researchers at the University ... first to examine microRNAs in the disease, is available online ... Medicine . MicroRNAs are short strands of genetic ...
... 2010) -- Using a rare metal that,s not utilized by ... could help unlock the identities of thousands of difficult-to-study proteins, ... diseases. The research was published online this week in ... "We have combined the chemical capabilities of rhodium with what ...
Cached Biology News:The kiss of death: Research targets lethal disease spread by insect that bites lips 2Pitt researchers discover big role for microRNA in lethal lung fibrosis 2Synthetic enzymes could help ID proteins 2
... to qualitatively detect EGFR ... paraffin-embedded (FFPE) tissue sections, ... cell preparations, using Chromogenic ... Fluorescent In Situ Hybridization ...
Request Info...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
...
Biology Products: